Brought to you by 
Bill & Melinda Gates Foundation leads $14mm Series A2 round for Just Biotherapeutics
19 Aug 2016
Executive Summary
Just Biotherapeutics Inc. (aims to reduce manufacturing and commercial costs of therapeutic proteins, including anti-HIV antibodies, by integrating molecular, process, drug, and manufacturing design elements) completed a $14mm Series A2 round led by the Bill & Melinda Gates Foundation, which invested $8mm. Returning Series A backers Merck & Co. Inc., Lilly Asia Ventures, and Arch Venture Partners each put in $2mm. The company will use the money to finish building a lab and pilot plant with proper GMP capabilities.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bill & Melinda Gates Foundation leads $14mm Series A2 round for Just Biotherapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice